Wedbush Reaffirms “Outperform” Rating for Entasis Therapeutics (ETTX)

Sofinnova Ventures Inc bought a new stake in shares of Entasis Therapeutics in the third quarter worth $12,840,000. Luminus Management LLC …

Entasis Therapeutics logoEntasis Therapeutics (NASDAQ:ETTX)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a report released on Tuesday, April 2nd. They presently have a $19.00 price objective on the stock. Wedbush’s price objective indicates a potential upside of 192.31% from the stock’s previous close. Wedbush also issued estimates for Entasis Therapeutics’ Q1 2019 earnings at ($0.68) EPS, Q2 2019 earnings at ($0.73) EPS, Q3 2019 earnings at ($0.54) EPS, Q4 2019 earnings at ($0.58) EPS, FY2019 earnings at ($2.47) EPS, FY2020 earnings at ($2.46) EPS, FY2021 earnings at ($1.55) EPS, FY2022 earnings at ($0.12) EPS and FY2023 earnings at $1.47 EPS.

Other research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Entasis Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Friday, January 4th. ValuEngine cut shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.50.

NASDAQ ETTX opened at $6.50 on Tuesday. Entasis Therapeutics has a 1-year low of $3.97 and a 1-year high of $13.70.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sofinnova Ventures Inc bought a new stake in shares of Entasis Therapeutics in the third quarter worth $12,840,000. Luminus Management LLC bought a new stake in shares of Entasis Therapeutics in the third quarter worth $2,130,000. Hound Partners LLC bought a new stake in shares of Entasis Therapeutics in the third quarter worth $1,117,000. Credit Suisse AG bought a new stake in shares of Entasis Therapeutics in the third quarter worth $757,000. Finally, Laurion Capital Management LP bought a new stake in shares of Entasis Therapeutics in the third quarter worth $544,000. 65.40% of the stock is currently owned by hedge funds and other institutional investors.

About Entasis Therapeutics

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

Featured Story: What is a front-end load?

Receive News & Ratings for Entasis Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Entasis Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

SunTrust Banks Comments on Entasis Therapeutics Holdings Inc’s FY2023 Earnings (ETTX)

Sofinnova Ventures Inc purchased a new stake in shares of Entasis Therapeutics in the third quarter valued at approximately $12,840,000. Finally …

Entasis Therapeutics logo

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) – Stock analysts at SunTrust Banks issued their FY2023 earnings estimates for shares of Entasis Therapeutics in a note issued to investors on Monday, April 1st, Zacks Investment Research reports. SunTrust Banks analyst E. Nash anticipates that the company will post earnings of ($3.09) per share for the year.

Several other research firms have also commented on ETTX. Zacks Investment Research upgraded Entasis Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Friday, January 4th. ValuEngine lowered Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $19.00 price objective on shares of Entasis Therapeutics in a research note on Tuesday, April 2nd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Entasis Therapeutics has an average rating of “Buy” and a consensus price target of $16.50.

NASDAQ ETTX opened at $6.50 on Wednesday. Entasis Therapeutics has a twelve month low of $3.97 and a twelve month high of $13.70.

A number of large investors have recently bought and sold shares of ETTX. Credit Suisse AG purchased a new stake in Entasis Therapeutics during the 3rd quarter worth approximately $757,000. Laurion Capital Management LP purchased a new stake in shares of Entasis Therapeutics in the third quarter valued at approximately $544,000. Hound Partners LLC purchased a new stake in shares of Entasis Therapeutics in the third quarter valued at approximately $1,117,000. Sofinnova Ventures Inc purchased a new stake in shares of Entasis Therapeutics in the third quarter valued at approximately $12,840,000. Finally, Luminus Management LLC purchased a new stake in shares of Entasis Therapeutics in the third quarter valued at approximately $2,130,000. Institutional investors own 65.40% of the company’s stock.

Entasis Therapeutics Company Profile

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

Further Reading: Google Finance Portfolio

Get a free copy of the Zacks research report on Entasis Therapeutics (ETTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Entasis Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Entasis Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Alteryx, Inc. (AYX) EPS Estimated At $-0.09 on May, 8

Alteryx, Inc. (NYSE:AYX) is expected to publish earnings on May, 8., Faxor reports. Last year’s earnings per share was $-0.07, while now analysts …

Alteryx, Inc. (NYSE:AYX) is expected to publish earnings on May, 8., Faxor reports. Last year’s earnings per share was $-0.07, while now analysts expect change of 28.57 % down from current $-0.09 earnings per share. Wall Street now predicts 12.50 % negative EPS growth despite Alteryx, Inc. previous quarter’s EPS of $-0.08. AYX reached $81.54 during the last trading session after $0.88 change.Currently Alteryx, Inc. is uptrending after 96.15% change in last April 11, 2018. AYX has 489,487 shares volume. AYX outperformed by 91.78% the S&P 500.

Alteryx, Inc. (NYSE:AYX) Ratings Coverage

In total 3 analysts cover Alteryx (NYSE:AYX). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. 67% are bullish. With $93 highest and $76 lowest price target Alteryx has $84.67 average price target or 3.84% above the current ($81.54) price. 4 are the (NYSE:AYX)’s analyst reports since February 28, 2019 according to StockzIntelligence Inc. The company rating was maintained by Citigroup on Friday, March 1. On Thursday, February 28 the firm has “Overweight” rating by KeyBanc Capital Markets given. The stock rating was maintained by Wedbush with “Neutral” on Thursday, February 28.

Alteryx, Inc. provides self-service data analytics software platform that enables organizations to enhance business outcomes and the productivity of their business analysts.The company has $5.04 billion market cap. It offers Alteryx Designer for data preparation, blending, and analytics that could be deployable in the cloud and on premise; Alteryx Server, a secure and scalable product for sharing and running analytic applications in a Web environment; and Alteryx Analytics Gallery, a cloud collaboration offering that allows users to share workflows in a centralized repository.189.63 is the P/E ratio. The firm serves clients in business and financial services, consumer goods, healthcare, retail, technology, and travel and hospitality industries in approximately 50 countries.

For more Alteryx, Inc. (NYSE:AYX) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Ocbj.com or Profitconfidential.com. The titles are as follows: “Alteryx: A Little SaaS Accounting Lesson – Seeking Alpha” published on March 04, 2019, “DDD: 3 Lessons From A Failed Growth Story – Seeking Alpha” on March 21, 2019, “Alteryx: A Shining Star – Seeking Alpha” with a publish date: July 30, 2018, “Midday Stock Roundup – Orange County Business Journal” and the last “AYX Stock: More Double-Digit Upside for This Data Specialist – Profit Confidential” with publication date: November 22, 2018.

Alteryx, Inc. (NYSE:AYX) Analyst Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Analysts Research Summary: Alteryx Inc. (NYSE:AYX)

Alteryx Inc. (NYSE:AYX) shares traded -0.68% down during most recent session to reach at the closing price of $80.66. The stock exchanged hands …

Alteryx Inc. (NYSE:AYX) shares traded -0.68% down during most recent session to reach at the closing price of $80.66. The stock exchanged hands 698997 shares versus average trading capacity of 1.13 Million shares, yielding a market cap of $5.02 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $86.6 within the next 52-weeks. The mean target projections are based on 10 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Alteryx Inc. (NYSE:AYX) high price target of $97 and with a conservative view have low price target of $74.

Citigroup “Maintained” Alteryx Inc. (NYSE:AYX) in a research note issued to investors on 3/01/19 to Buy with price target of $93.

Additionally on 2/28/19 KeyBanc “Maintained” Alteryx Inc. (NYSE:AYX) to Overweight setting price target at $85 and on 2/28/19 Wedbush “Maintained” the stock to Neutral at $76. Furthermore on 2/11/19 Wedbush “Downgrades” the stock to Neutral at $0.

On the other hand the company has Relative Strength Index (RSI 14) of 54.01 along with Average True Range (ATR 14) of 3.51, Consequently Alteryx Inc. (NYSE:AYX)’s weekly and monthly volatility is 4.03%, 4.14% respectively. The company’s beta value is at 0.

In terms of Buy, Sell or Hold recommendations, Alteryx Inc. (NYSE:AYX) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Alteryx Inc. (NYSE:AYX)’s minimum EPS for the current quarter is at $-0.11 and can go high up to $-0.04. The consensus mean EPS for the current quarter is at $-0.08 derived from a total of 13 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.01 earnings per share for the same quarter during last year.

Previously Alteryx Inc. (NYSE:AYX) reported $-0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.02 by $0.01. The company posted an earnings surprise of 50%.

Alteryx Inc. (NYSE:AYX)’s revenue estimates for the current quarter are $71.28 Million according to 12 number of analysts, for the current quarter the company has high revenue estimates of $74.23 Million in contradiction of low revenue estimates of $69.5 Million. For the current year the company’s revenue estimates are $349.8 Million compared to low analyst estimates of $346.49 Million and high estimates of $360.19 Million according to 12 number of analysts.

Currently Alteryx Inc. (NYSE:AYX)’s shares owned by insiders are 0.9%, whereas shares owned by institutional owners are 0%. However the six-month change in the insider ownership was recorded -70.4%, as well as three-month change in the institutional ownership was recorded 2.69%.

Alteryx Inc. (NYSE:AYX)’s trailing twelve month revenues are $253.6 Million, whereas its price to sales ratio for the same period is 19.8. Its book value per share for the most recent quarter is $4.91 while its price to book ratio for the same period is 16.43, as for as the company’s cash per share for the most recent quarter is $5.3, however its price to cash per share ratio for the same period is 15.23. The stock has 5 year expected PEG ratio of 10.84 whereas its trailing twelve month P/E ratio is 248.18.

Related Posts:

  • No Related Posts

Wedbush Securities Increases Holding in Intl Business Machines (IBM); Biglari Capital Decreased …

Mach IBM Board Approves Increase in Quarterly Cash Dividend for the 23rd Consecutive Year; 22/05/2018 – Apollo Hospitals Adopts IBM Watson for …

Wedbush Securities Inc increased its stake in Intl Business Machines (IBM) by 25.19% based on its latest 2018Q4 regulatory filing with the SEC. Wedbush Securities Inc bought 4,975 shares as the company’s stock rose 12.54% with the market. The institutional investor held 24,726 shares of the computer manufacturing company at the end of 2018Q4, valued at $2.81M, up from 19,751 at the end of the previous reported quarter. Wedbush Securities Inc who had been investing in Intl Business Machines for a number of months, seems to be bullish on the $126.90B market cap company. The stock decreased 0.55% or $0.79 during the last trading session, reaching $142.6. About 1.30M shares traded. International Business Machines Corporation (NYSE:IBM) has declined 10.00% since April 9, 2018 and is downtrending. It has underperformed by 14.37% the S&P500. Some Historical IBM News: 17/04/2018 – IBM 1Q EPS $1.81; 16/05/2018 – FINJAN HOLDINGS INC SAYS TERMS OF PATENT ASSIGNMENT AGREEMENT ARE CONFIDENTIAL – SEC FILING; 17/04/2018 – IBM CFO JAMES KAVANAUGH: DISAPPOINTED W/ STORAGE REVENUE GROWTH; 24/04/2018 – REG-lntnl Bus. Mach IBM Board Approves Increase in Quarterly Cash Dividend for the 23rd Consecutive Year; 22/05/2018 – Apollo Hospitals Adopts IBM Watson for Oncology and IBM Watson for Genomics to Help Physicians Make Data-Driven Cancer Care Decisions; 27/03/2018 – ShiftPixy Leverages IBM’s Watson to Better Connect and Scale; 22/05/2018 – Quad Nova’s CEO Says Workarounds on the IBM i (AS/400) May Compromise Enterprise Value; 18/04/2018 – Markets Now: Dow Gains 20 Points as IBM Caps Upside — Barron’s Blog; 27/03/2018 – ITALY’S CARIGE SAYS ACKNOWLEDGES MARKET CONDITIONS ARE NOT THERE FOR ISSUANCE OF SUBORDINATED BOND WITH “EXPECTED CHARACTERISTICS”; 18/04/2018 – XTD LTD XTD.AX – SIGNED COLLABORATION AGREEMENT WITH IBM FOR GLOBAL DISTRIBUTION OF SMART CITIES SOFTWARE SOLUTIONS

Biglari Capital Corp decreased its stake in Investors Title Co (ITIC) by 18.58% based on its latest 2018Q4 regulatory filing with the SEC. Biglari Capital Corp sold 5,574 shares as the company’s stock declined 6.99% while stock markets rallied. The hedge fund held 24,426 shares of the specialty insurers company at the end of 2018Q4, valued at $4.32M, down from 30,000 at the end of the previous reported quarter. Biglari Capital Corp who had been investing in Investors Title Co for a number of months, seems to be less bullish one the $300.54 million market cap company. The stock decreased 0.16% or $0.26 during the last trading session, reaching $159.3. About 3,438 shares traded. Investors Title Company (NASDAQ:ITIC) has declined 6.89% since April 9, 2018 and is downtrending. It has underperformed by 11.26% the S&P500. Some Historical ITIC News: 05/03/2018 Investors Title Company Declares Quarterly Dividend; 09/05/2018 – Investors Title Short-Interest Ratio Rises 35% to 10 Days; 08/05/2018 – Investors Title 1Q EPS $2.20; 08/05/2018 – Investors Title 1Q Rev $33.8M; 19/04/2018 – DJ Investors Title Company, Inst Holders, 1Q 2018 (ITIC)

Investors sentiment decreased to 0.59 in 2018 Q4. Its down 0.32, from 0.91 in 2018Q3. It dropped, as 129 investors sold IBM shares while 678 reduced holdings. 121 funds opened positions while 353 raised stakes. 523.62 million shares or 6.28% more from 492.69 million shares in 2018Q3 were reported. Barbara Oil holds 0.38% or 5,000 shares. Old Second Financial Bank Of Aurora, a Illinois-based fund reported 2,243 shares. Meridian Inv Counsel stated it has 7,416 shares or 0.55% of all its holdings. Central National Bank & Trust Tru reported 1,281 shares. 42,624 are owned by Thompson Rubinstein Mgmt Or. Union Retail Bank Corporation has 4,417 shares. Parthenon Limited Liability Corporation reported 29,199 shares. Dorsey Whitney Trust Company Ltd Liability Corp reported 12,416 shares. Stevens Mgmt Lp invested 0.02% of its portfolio in International Business Machines Corporation (NYSE:IBM). Sfmg Ltd invested in 2,326 shares. Voya Investment Management Limited reported 0.14% in International Business Machines Corporation (NYSE:IBM). 18,241 are owned by Freestone Ltd Liability. Advisory Net Ltd Liability stated it has 29,429 shares or 0.29% of all its holdings. Moreover, First Amer Bankshares has 0.08% invested in International Business Machines Corporation (NYSE:IBM). Lodestar Counsel Limited Il reported 5,419 shares stake.

More notable recent International Business Machines Corporation (NYSE:IBM) news were published by: Bizjournals.com which released: “State has not yet signed contract with IBM for partnership at SUNY Poly – Albany Business Review” on March 26, 2019, also Benzinga.com with their article: “International Business Machines Corporation (NYSE:IBM), Western Union Company (The) (NYSE:WU) – XRP/USD Stages A Recovery As XRP Futures Go Live On Huobi Exchange – Benzinga” published on March 27, 2019, Fool.com published: “Better Dividend Buy: IBM vs. Coca-Cola – Motley Fool” on March 14, 2019. More interesting news about International Business Machines Corporation (NYSE:IBM) were released by: Fool.com and their article: “A Low-Risk Way to Bet on Fintech and Blockchain – The Motley Fool” published on March 19, 2019 as well as 247Wallst.com‘s news article titled: “Alphabet, IBM and Other Tech Stocks With Recent Golden Crosses – 24/7 Wall St.” with publication date: April 04, 2019.

Since October 31, 2018, it had 5 insider buys, and 0 insider sales for $2.09 million activity. Shares for $114,673 were bought by OWENS JAMES W. On Wednesday, October 31 TAUREL SIDNEY bought $495,846 worth of International Business Machines Corporation (NYSE:IBM) or 4,311 shares. 2,000 shares were bought by Swedish Joseph, worth $232,838. 2,153 International Business Machines Corporation (NYSE:IBM) shares with value of $249,722 were bought by WADDELL FREDERICK H.

Wedbush Securities Inc, which manages about $782.42 million US Long portfolio, decreased its stake in Northrim Bancorp Inc (NASDAQ:NRIM) by 11,115 shares to 56,549 shares, valued at $1.86M in 2018Q4, according to the filing. It also reduced its holding in Schlumberger Ltd (NYSE:SLB) by 11,726 shares in the quarter, leaving it with 24,294 shares, and cut its stake in Willdan Group Inc (NASDAQ:WLDN).

More notable recent Investors Title Company (NASDAQ:ITIC) news were published by: Seekingalpha.com which released: “Calloway’s Nursery: Under The Radar And Trading Below Liquidation Value – Seeking Alpha” on January 27, 2017, also Nasdaq.com with their article: “Philippines’ Duterte picks cabinet ally to head central bank – Nasdaq” published on March 04, 2019, Gurufocus.com published: “Mar 07, 2019 – Goldman Sachs Group Inc Buys Energy Transfer LP, iShares iBoxx $ High Yield Corporate Bond, Merck Inc, Sells Energy Transfer Operating LP, Express Scripts Holding Co, iShares iBoxx $ Investment Grade Corporate Bond – GuruFocus.com” on March 07, 2019. More interesting news about Investors Title Company (NASDAQ:ITIC) were released by: Marketwatch.com and their article: “Apple and other companies sound the alarm on Trump’s China tariff plans – MarketWatch” published on September 11, 2018 as well as Businesswire.com‘s news article titled: “Investors Title Company Board Declares Special Cash Dividend and Regular Quarterly Cash Dividend – Business Wire” with publication date: November 13, 2018.

Investors sentiment increased to 1.47 in 2018 Q4. Its up 0.36, from 1.11 in 2018Q3. It is positive, as 1 investors sold ITIC shares while 18 reduced holdings. 12 funds opened positions while 16 raised stakes. 800,687 shares or 0.50% more from 796,679 shares in 2018Q3 were reported. Rhumbline Advisers accumulated 0% or 1,955 shares. Strs Ohio has 0% invested in Investors Title Company (NASDAQ:ITIC). Wells Fargo Mn has 19,227 shares. Dimensional Fund Advsrs Ltd Partnership invested in 0.01% or 149,402 shares. Bancorporation Of America Corporation De reported 0% stake. Rbf Capital Limited Company has invested 0.09% in Investors Title Company (NASDAQ:ITIC). Biglari has invested 0.47% in Investors Title Company (NASDAQ:ITIC). Tiaa Cref Investment invested in 2,960 shares or 0% of the stock. Citigroup Incorporated reported 381 shares. Fmr Ltd Liability Co reported 0% in Investors Title Company (NASDAQ:ITIC). Marshall Wace Ltd Liability Partnership accumulated 5,228 shares. Davenport Limited Liability invested 0.01% in Investors Title Company (NASDAQ:ITIC). Alliancebernstein Lp stated it has 0% of its portfolio in Investors Title Company (NASDAQ:ITIC). Invesco Ltd holds 0% in Investors Title Company (NASDAQ:ITIC) or 9,114 shares. Whittier Tru accumulated 400 shares.

International Business Machines Corporation (NYSE:IBM) Institutional Positions Chart

Related Posts:

  • No Related Posts